Vertex Pharmaceuticals Incorporated
VRTX Healthcare Biotechnology
Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.
Follow VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Price to free cash flow
As of 16 October 2026, Vertex Pharmaceuticals Incorporated (VRTX) trades at a price to free cash flow of 33.4×. Over the past ten years it has ranged from 0.0× (June 2025) to 353× (November 2016); the current reading is higher than 65% of that period. That is above the Biotechnology industry median of 20.8× and above the Healthcare sector median of 20.2×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 36.3× | — |
| FY2024 | 0.0× | — |
| FY2023 | 31.7× | 70.05% |
| FY2022 | 18.7× | (20.58%) |
| FY2021 | 23.5× | 14.56% |
| FY2020 | 20.5× | (45.48%) |
| FY2019 | 37.6× | 4.89% |
| FY2018 | 35.9× | (29.73%) |
| FY2017 | 51.0× | (49.99%) |
| FY2016 | 102× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 33.2× | 8.55% |
| Mar 2026 | 30.6× | (15.75%) |
| Dec 2025 | 36.3× | 21.00% |
| Sep 2025 | 30.0× | (8.14%) |
| 42 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| ROIV Roivant Sciences Ltd. compare | n/m |
| MRNA Moderna, Inc. compare | n/m |
| RVMD Revolution Medicines, Inc. compare | n/m |
| RPRX Royalty Pharma PLC compare | 20.8× |
| REGN Regeneron Pharmaceuticals, Inc. compare | 22.7× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 31.4× |
| VRTX Vertex Pharmaceuticals Incorporated | 33.4× |
| ARGX argenex SE compare | 37.0× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 37.8× |
| Biotechnology industry median | 20.8× |
| Healthcare sector median | 20.2× |
| Market median | 14.2× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on VRTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement